Hostname: page-component-7c8c6479df-ws8qp Total loading time: 0 Render date: 2024-03-28T14:08:00.521Z Has data issue: false hasContentIssue false

EPA-1446 - Antiparkinsonian Drug Related Hallucination

Published online by Cambridge University Press:  15 April 2020

J. Batistela
Affiliation:
Basic Sciences, Albert Einstein Hospital, Sao Paulo, Brazil
F. Ropero Pel ez
Affiliation:
Mathematics Computation and Cognition, Universidade Federal do ABC, Santo andré, Brazil
A. Tamarindo
Affiliation:
Basic Sciences, Albert Einstein Hospital, Sao Paulo, Brazil
S. Silva
Affiliation:
Basic Sciences, Albert Einstein Hospital, Sao Paulo, Brazil
E. Frizzo
Affiliation:
Basic Sciences, Albert Einstein Hospital, Sao Paulo, Brazil
S. Salman
Affiliation:
Geriatrics, Premier Hospital, Sao Paulo, Brazil
S. Taniguchi
Affiliation:
Basic Sciences, Albert Einstein Hospital, Sao Paulo, Brazil

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Antiparkinsonian drugs increase dopaminergic system activity in order to compensate dopamine neurons degeneration in corpus striatum.

Objectives

To study antiparkinsonian drugs hallucinatory side effect

Methods

Our study included 28 geriatric patients enrolled in a private long-term care institution with mean age 84.93 ± 5.71 years old, weight mean 66.36 ± 2.83 kg with Parkinson’s disease.

Results

Drugs administered to patients with Parkinson’s disease were studied.

The association of L-DOPA and DOPA descarboxylase inhibitor (benserazide) were administered to 53%(15) in doses between 2.0-19.0 mg/kg/day.

L-DOPA associated to catechol-O-methyltransferase inhibitor (entacapone)

3 mg/kg/day were given to 7.14% (2) patients.

Bromocriptine 0.04 mg/kg/day were given to 3.57% (1) patient.

39.29% (11) did not received any antiparkinsonian drug.

Mental confusion and hallucination side effect were observed in 53.33%(8) patients treated with L-DOPA associated to DOPA descarboxylase inhibitor (benserazide).

Conclusion

The increase of dopamine levels due to the administration L-DOPA, in corpus striatum improved Parkinson’s disease symptoms although undesirable effect related to dopamine activity at mesocortical pathway such as confusion and hallucination were observed.

Type
EPW23 - Geriatric Psychiatry 2
Copyright
Copyright © European Psychiatric Association 2014
Submit a response

Comments

No Comments have been published for this article.